NYSE:DPLO - Diplomat Pharmacy Stock Price, News, & Analysis

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Tuesday, November, 6th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.21. The business earned $1.37 billion during the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. The company's quarterly revenue was up 22.0% on a year-over-year basis. During the same period last year, the firm posted $0.01 earnings per share. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy will be holding an earnings conference call on Monday, February 25th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8332865805.

Diplomat Pharmacy issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.5-5.6 billion, compared to the consensus revenue estimate of $5.56 billion.

11 brokers have issued 12-month price objectives for Diplomat Pharmacy's stock. Their predictions range from $15.00 to $33.00. On average, they anticipate Diplomat Pharmacy's share price to reach $21.25 in the next year. This suggests a possible upside of 48.6% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

News headlines about DPLO stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Diplomat Pharmacy earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.

Some companies that are related to Diplomat Pharmacy include Rite Aid (RAD), 111 (YI), Petmed Express (PETS), Taxus Pharmaceuticals (TXSP), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Diplomat Pharmacy's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.62%), Dimensional Fund Advisors LP (2.86%), Bank of New York Mellon Corp (2.26%), Northern Trust Corp (1.73%), Rhenman & Partners Asset Management AB (1.62%) and Frontier Capital Management Co. LLC (1.57%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, D. E. Shaw & Co. Inc., Bank of America Corp DE, Empirical Capital Management LLC, GW&K Investment Management LLC, Mackay Shields LLC, Barclays PLC and MetLife Investment Advisors LLC. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Advisory Services Network LLC, Dimensional Fund Advisors LP, Royce & Associates LP, BlackRock Inc., Geode Capital Management LLC, Tekla Capital Management LLC and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $14.30.

Diplomat Pharmacy has a market capitalization of $1.06 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]